Key Highlights
- Shares closed at $1.26 at last closing, down 0.79%, in penny-stock territory.
- MaxCyte reiterated its 2026 Revenue outlook of roughly $30 million to $32 million.
- The company highlighted an expanding Partnership involving a major pharmaceutical company.
- Revenue can be lumpy given strategic-platform-license arrangements that include milestone payments.
Penny stock MaxCyte (NASDAQ:MXCT) is a life-sciences company that provides cell-engineering technology, primarily its electroporation-based platform used to deliver molecules into cells, important in the development of cell therapies and gene-edited therapies. Shares closed at $1.26 at last closing, down 0.79%.
Its revenue comes from selling and leasing its instruments and consumables and, notably, from strategic-platform-license arrangements with cell-therapy developers that can include milestone and other payments, making revenue partly lumpy.
Latest Developments
In its second-quarter 2026 results, MaxCyte reiterated its 2026 revenue outlook of roughly $30 million to $32 million and highlighted an expanding partnership involving a major pharmaceutical company. Investors should confirm the latest core revenue and its growth, strategic-platform-license and milestone contributions, gross margins, and cash position directly from SEC filings.
Financial and Business Position
MaxCyte's financial position is defined by its instrument and consumable revenue, its strategic-platform-license arrangements that can bring milestone payments, and its ongoing losses as a growth-stage company. Investors should watch core revenue and growth, license and milestone contributions, and the net loss and cash burn.
Stock-Market Context
MXCT shares closed at $1.26 at last closing, down 0.79%, keeping the stock in penny territory. The stock is a small-cap life-sciences company whose shares are volatile and sensitive to revenue trends and the lumpiness of milestone payments.
What Investors Should Watch
Watch core revenue and its growth, strategic-platform-license and milestone contributions, gross margins, the net loss and cash burn, and partnership developments. Consistent core-revenue growth combined with progress on partner therapies that triggers milestones, and a healthier cell-therapy sector, would be the most direct factors that could reverse the momentum.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...